Peptide Bio IndexEvidence first. Hype last.
⌕

Retatrutide and Liver-Fat Research: What Published Studies Report

Written by

in

Peptide Research Overviews
PBIPeptide Bio Index Editorial DeskSource-labeled research summary
Source-labeled8 min readUpdated Sep 7, 2026
Jump to a section
  1. Primary liver‑fat outcomes reported in the randomized phase 2a substudy
  2. How liver‑fat changes related to weight and metabolic measures
  3. Trial designs, dosing, and measured timepoints relevant to liver‑fat outcomes
  4. Safety, tolerability, and body‑composition considerations reported in trials
  5. Context and next steps in clinical development relevant to liver disease
  6. Reported study-design details from cited sources
  7. Limitations and research gaps
  8. Documentation checklist
  9. Related research supplies
  10. More Retatrutide research
  11. Sources and references

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.

This evidence deep dive summarizes published clinical findings that evaluated retatrutide (a GIP/GLP-1/glucagon triple-receptor agonist) for changes in liver fat and related metabolic measures in humans, focusing on randomized clinical data and closely related phase 2 obesity and diabetes trials that contextualize liver-fat effects.

Primary liver‑fat outcomes reported in the randomized phase 2a substudy

In a randomized, double-blind, placebo-controlled phase 2a substudy of participants with metabolic dysfunction-associated steatotic liver disease and baseline liver fat ≥10%, retatrutide produced dose-dependent relative reductions in liver fat at 24 weeks: −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg), versus +0.3% with placebo; all active-dose comparisons were reported as P < 0.001 versus placebo. At 24 weeks, the proportions achieving normal liver fat (<5%) were 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg), and 0% (placebo). [S3]

Investigators reported that liver-fat reductions in the substudy were significantly related to concurrent changes in body weight, reductions in abdominal fat, and improvements in metabolic measures associated with insulin sensitivity and lipid metabolism; these associations were described by the authors as contributors to the observed liver-fat improvements. Larger phase 2 obesity and diabetes trials of retatrutide demonstrated substantial, dose-dependent body-weight reductions and improvements in glycaemic control that provide context for metabolic change (for example, marked percent weight loss at 24–48 weeks in S2 and clinically meaningful HbA1c and weight reductions across doses in people with type 2 diabetes in S1). [S3] [S2] [S1]

Trial designs, dosing, and measured timepoints relevant to liver‑fat outcomes

The liver‑fat substudy enrolled participants from a 48‑week phase 2 obesity study and randomized 98 participants to once‑weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo; the substudy’s primary liver‑fat endpoint was mean relative change from baseline in liver fat at 24 weeks. The parent obesity study used once‑weekly subcutaneous dosing and assessed weight outcomes at 24 and 48 weeks. [S3] [S2]

Safety, tolerability, and body‑composition considerations reported in trials

Across published phase 2 trials, the most common adverse events with retatrutide were dose‑related gastrointestinal events that were typically mild to moderate; S2 reported dose‑related gastrointestinal effects and transient, dose‑dependent increases in heart rate that peaked at 24 weeks then declined. In the phase 2 diabetes trial (S1), retatrutide showed a safety profile consistent with GLP‑1 receptor agonists and related agents, with no severe hypoglycaemia or deaths reported in that study. Independent reviews and reviews of incretin‑based therapies emphasize that rapid, large weight loss with these agents can be accompanied by loss of lean mass and that consideration of body‑composition effects (for example, resistance exercise to preserve lean mass) has been discussed in the literature. [S2] [S1] [S7]

Context and next steps in clinical development relevant to liver disease

Retatrutide’s clinical program is advancing beyond phase 2: phase 3 TRIUMPH trials were described as a multicenter registrational program evaluating weekly subcutaneous retatrutide versus placebo across multiple adiposity‑related indications (weight management and nested OSA and OA protocols), and reviews synthesize retatrutide as a triple‑receptor agonist with ongoing development to define longer‑term efficacy and safety across broader populations. Published phase 2 liver‑fat data (S3) provide randomized evidence of substantial short‑term reductions in liver fat, while phase 3 trials will further define clinical outcomes and safety in larger, longer studies. [S6] [S4] [S5]

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Source Study Type Model / Subject Amount Reported Route Reported Frequency Duration Notes
[S3] Randomized, double-blind, placebo-controlled phase 2a trial (liver-fat substudy) Adults with metabolic dysfunction-associated steatotic liver disease enrolled from a phase 2 obesity study (randomized substudy) 1 mg, 4 mg, 8 mg, 12 mg (once-weekly dosing arms) subcutaneous once weekly 24 weeks (primary liver-fat endpoint reported at 24 weeks); parent study duration 48 weeks Participants had baseline liver fat ≥10%; n = 98 randomized; liver-fat assessed as mean relative change from baseline at 24 weeks; proportions achieving liver fat
[S2] Randomized, double-blind, placebo-controlled phase 2 trial (obesity) Adults with obesity (phase 2 obesity trial population) 1 mg, 4 mg, 8 mg, 12 mg (with specified starting-dose escalation strategies reported) subcutaneous once weekly 48 weeks (primary obesity study reported weight outcomes at 24 and 48 weeks) Doses included 1 mg, 4 mg (initial dose 2 or 4 mg in different arms), 8 mg (initial dose 2 or 4 mg), and 12 mg (initial dose 2 mg); primary obesity endpoint reported at 24 weeks; safety included dose-related GI events and heart-rate changes.
[S1] Randomized, double-blind, placebo and active-controlled phase 2 trial (type 2 diabetes) Adults with type 2 diabetes (phase 2 diabetes trial population) 0.5 mg, 4 mg, 8 mg, 12 mg (maintenance-dose groups with stated starting-dose escalation in some arms) not reported in the reviewed source once weekly (described as once-weekly injections) 24 weeks primary endpoint; secondary endpoints reported at 36 weeks Multiple retatrutide maintenance doses evaluated (0.5 mg, 4 mg, 8 mg, 12 mg) with various escalation strategies; primary endpoint was change in HbA1c at 24 weeks and secondary endpoints included weight at 36 weeks; safety profile described as consistent with GLP-1 receptor agonists.
[S6] Phase 3 registrational program (protocol description) Planned registrational Phase 3 program (TRIUMPH) enrolling adults with obesity and related complications not reported in the reviewed source subcutaneous weekly not reported in the reviewed source TRIUMPH consists of four multicenter randomized double-blind trials assessing weekly subcutaneous retatrutide versus placebo across weight management and nested OSA and OA protocols; total planned enrollment >5800 participants; primary endpoints vary by nested protocol (percent weight change, AHI for OSA, WOMAC pain subscale for knee OA).

Limitations and research gaps

  • Available randomized evidence for liver‑fat change comes from a phase 2a substudy with 98 randomized participants; larger and longer trials are needed to establish durability and broader generalizability.
  • Reported liver‑fat outcomes are presented as group‑level changes and associations with weight and metabolic markers; causality and individual response variability require further study.
  • Some contextual safety signals (for example, effects on lean mass and long‑term cardio‑metabolic outcomes) are drawn from related incretin literature and warrant dedicated prospective assessment with retatrutide in larger datasets.

Documentation checklist

  • Open the cited randomized liver-fat substudy (S3) for the primary liver-fat outcomes at 24 weeks.
  • Confirm inclusion criteria: participants had metabolic dysfunction-associated steatotic liver disease and baseline liver fat ≥10%.
  • Compare reported liver-fat percent-change results across the 1, 4, 8 and 12 mg retatrutide arms and placebo in S3.
  • Note key timepoints reported for liver-fat (24 weeks) and for body-weight outcomes (24 and 48 weeks in S2).
  • Review safety and tolerability summaries in S1 and S2 (gastrointestinal adverse events; heart-rate changes noted in S2).
  • MRI-compatible patient positioning pads and liver‑fat imaging checklists (documentation/organization only)
  • Clinical trial specimen labelling and freezer inventory templates (documentation/organization only)
  • Electronic data capture case report form (CRF) templates for liver fat and metabolic endpoints (documentation only)

Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.

Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.

Batch and inventory labeling

Phomemo M110 Label and Barcode Printer

A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.

View on Amazon (paid link)

Label-printer refill

Phomemo M110 White Replacement Labels

White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.

View on Amazon (paid link)

Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.

Research Supply Note: SourcePoint Research currently lists SPR-3RT for research-use-only sourcing. Review current availability and the exact batch documentation at SourcePointResearch.com. This article does not independently certify a SourcePoint batch. Peptide Bio Index is affiliated with SourcePoint Research.

More Retatrutide research

Sources and references

  1. [S1] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. Lancet (London, England). 2023. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X
  2. [S2] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
  3. [S3] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine. 2024. PMID: 38858523. DOI: 10.1038/s41591-024-03018-2
  4. [S4] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
  5. [S5] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
  6. [S6] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
  7. [S7] Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care. 2024. PMID: 38687506. DOI: 10.2337/dci23-0100
  8. [S8] Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity?. International journal of obesity (2005). 2025. PMID: 38302593. DOI: 10.1038/s41366-024-01473-y

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.

More posts